ATE392476T1 - Dna immunisierung gegen chlamydia infektion - Google Patents

Dna immunisierung gegen chlamydia infektion

Info

Publication number
ATE392476T1
ATE392476T1 AT00962134T AT00962134T ATE392476T1 AT E392476 T1 ATE392476 T1 AT E392476T1 AT 00962134 T AT00962134 T AT 00962134T AT 00962134 T AT00962134 T AT 00962134T AT E392476 T1 ATE392476 T1 AT E392476T1
Authority
AT
Austria
Prior art keywords
stk
host
immunization against
dna immunization
chlamydia infection
Prior art date
Application number
AT00962134T
Other languages
English (en)
Inventor
Robert Brunham
Original Assignee
Univ Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba filed Critical Univ Manitoba
Application granted granted Critical
Publication of ATE392476T1 publication Critical patent/ATE392476T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00962134T 1999-09-22 2000-09-21 Dna immunisierung gegen chlamydia infektion ATE392476T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/401,780 US6632663B1 (en) 1999-09-22 1999-09-22 DNA immunization against chlamydia infection

Publications (1)

Publication Number Publication Date
ATE392476T1 true ATE392476T1 (de) 2008-05-15

Family

ID=23589205

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00962134T ATE392476T1 (de) 1999-09-22 2000-09-21 Dna immunisierung gegen chlamydia infektion

Country Status (8)

Country Link
US (2) US6632663B1 (de)
EP (1) EP1222283B1 (de)
AT (1) ATE392476T1 (de)
AU (1) AU774309B2 (de)
CA (1) CA2385655C (de)
DE (1) DE60038620T2 (de)
NZ (1) NZ518283A (de)
WO (1) WO2001021811A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
AU5365999A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding pomp91a protein of (chlamydia)
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
US20020094340A1 (en) 1998-12-01 2002-07-18 Andrew D. Murdin Chlamydia antigens and corresponding dna thereof
ATE318924T1 (de) * 1998-12-04 2006-03-15 Univ Manitoba Zwei-schritte-verfahren zur impfung gegen chlamydia
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
AU769293B2 (en) 1998-12-08 2004-01-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1140998B1 (de) 1998-12-28 2008-01-23 Aventis Pasteur Limited Chlamydia antigene, entsprechende dna fragmente und ihre verwendungen
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
EP1163342B1 (de) 1999-03-12 2008-12-10 Aventis Pasteur Limited Chlamydia antigene und deren korrespondierende dna fragmente und verwendungen davon
US20030095973A1 (en) 1999-05-03 2003-05-22 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001046224A2 (en) 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
CA2408199A1 (en) 2000-05-08 2001-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE143414T1 (de) 1985-01-14 1996-10-15 Chiron Corp Hauptprotein der aussenmembran von chlamydia
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6001372A (en) * 1995-08-25 1999-12-14 Wisconsin Alumni Research Foundation Antigenic peptides of Chlamydia trachomatis
EP0915978B1 (de) 1996-07-12 2005-12-14 University of Manitoba Dna immunisierung gegen chlamydia infektion
JP2002536958A (ja) 1997-11-21 2002-11-05 ジェンセット Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用
EP2218732A1 (de) * 1997-11-28 2010-08-18 Merck Serono Biodevelopment Genomsequenz von Chlamydia trachomatis sowie Polypeptide, Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
AU769293B2 (en) 1998-12-08 2004-01-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
US20030095973A1 (en) 1999-05-03 2003-05-22 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2385325C (en) 1999-09-20 2012-04-10 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US6294265B1 (en) 1999-09-23 2001-09-25 Rademate Ltd. Hydrophobic biodegradable cellulose containing composite materials
WO2001046224A2 (en) 1999-12-22 2001-06-28 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
CA2408199A1 (en) 2000-05-08 2001-11-15 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae

Also Published As

Publication number Publication date
EP1222283B1 (de) 2008-04-16
AU774309B2 (en) 2004-06-24
DE60038620T2 (de) 2009-06-10
AU7399200A (en) 2001-04-24
US7229975B1 (en) 2007-06-12
NZ518283A (en) 2003-10-31
EP1222283A1 (de) 2002-07-17
WO2001021811A1 (en) 2001-03-29
CA2385655C (en) 2010-08-24
US6632663B1 (en) 2003-10-14
DE60038620D1 (de) 2008-05-29
CA2385655A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
DE60038620D1 (de) Dna immunisierung gegen chlamydia infektion
ATE312920T1 (de) Dna immunisierung gegen chlamydia infektion
Fragnet et al. The RNA subunit of telomerase is encoded by Marek's disease virus
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
DE69931112D1 (de) Chimäre Adenoviren
BR0208874A (pt) Proteìnas superficiais de streptococcus pyogenes
PE20060277A1 (es) Adenovirus quimericos en el tratamiento del cancer
DK1137792T3 (da) En rekombinant vektor, der udtrykker adskillige costimulatoriske molekyler, og anvendelser deraf
AR058249A2 (es) Una molecula aislada de polinucleotido que comprende una secuencia de adn que codifica una molecula infecciosa de arn que codifica un virus prrs norteamericano, celula transfectada y vacuna
WO1999058658A3 (en) Expression vectors for stimulating an immune response and methods of using the same
AU6681794A (en) Nucleotide vector, composition containing such vector and vaccine for immunization against hepatitis
TR200401186T4 (tr) Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları.
AU1013701A (en) Modified gp100 and uses thereof
GB9922361D0 (en) Generating an immune response to an antigen
WO1999051745A3 (en) Dna immunization against chlamydia infection
ATE346931T1 (de) Clostridium perfringens impfstoff
ES2148164T3 (es) Cepa atenuada de vacuna del virus del sarampion, que contiene una secuencia nucleotidica especifica y procedimiento para su identificacion.
DK0843731T3 (da) Adenovirusvektorer til genterapi
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
WO2001046225A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
CY1107845T1 (el) Γενετικα εμβολια με ανοσοενισχυτικο
DE60031369D1 (de) Replikation -defektive baculoviren expressionssystem
WO1999057284A3 (en) Attenuated influenza viruses
HU9900534D0 (en) Aviadenovirus
WO2000006742A3 (en) Chlamydia antigens and corresponding dna fragments and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties